Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22501724 | 0.79 | HPGDS (0.50) | MAPK1AOC3CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL1804513 | 0.78 | PRKCI (0.53) | MAPK1HPGDSHCRTR1HCRTR2CYP3A4 | |
| SCHEMBL25488454 | 0.78 | MAPK1 (0.43) | MAPK1HPGDSHCRTR1HCRTR2CYP3A4 | |
| SCHEMBL9507339 | 0.77 | HPGDS (0.53) | CYP1A2CYP2C19HPGDSHDAC4HCRTR1 | |
| SCHEMBL12469027 | 0.76 | SMN1; SMN2 (0.57) | MAPK1ALDH1A1CYP1A2TSHRCYP2C19 | |
| SCHEMBL6221648 | 0.76 | HPGDS (0.44) | MAPK1HPGDSHDAC4HCRTR1HCRTR2 | |
| SCHEMBL22501609 | 0.76 | PRMT6 (0.62) | MAPK1AOC3CYP2D6CYP2C9KDM4C | |
| SCHEMBL9863754 | 0.75 | HPGDS (0.46) | MAPK1TSHRHPGDSHCRTR1HCRTR2 | |
| SCHEMBL9454674 | 0.75 | HPGDS (0.46) | MAPK1ALDH1A1TSHRHPGDSHCRTR1 | |
| SCHEMBL12648428 | 0.75 | NOTUM (0.50) | MAPK1ALDH1A1HPGDHPGDSMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11945806-B2 | Stabilization of amyloidogenic immunoglobulin light chains | THE SCRIPPS RESEARCH INSTITUTE | 2024-04-02 | — | — | US | disclosed |
| US-20220204485-A1 | STABILIZATION OF AMYLOIDOGENIC IMMUNOGLOBULIN LIGHT CHAINS | THE SCRIPPS RESEARCH INSTITUTE | 2022-06-30 | — | — | US | disclosed |
| EP-3946604-A1 | BENZOPYRANE AND IMIDAZOLE DERIVATIVES USEFUL FOR THE STABILIZATION OF AMYLOIDOGENIC IMMUNOGLOBULIN LIGHT CHAINS | The Scripps Research Institute (US) | 2022-02-09 | — | — | EP | disclosed |
| WO-2020205683-A1 | BENZOPYRANE AND IMIDAZOLE DERIVATIVES USEFUL FOR THE STABILIZATION OF AMYLOIDOGENIC IMMUNOGLOBULIN LIGHT CHAINS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204485-A1 | STABILIZATION OF AMYLOIDOGENIC IMMUNOGLOBULIN LIGHT CHAINS | TTR, MAP1LC3B, SAAL1 | MAPK1 1900/4885AOC3 3864/4885ALDH1A1 2072/4885 |
| US-11945806-B2 | Stabilization of amyloidogenic immunoglobulin light chains | TTR, MAP1LC3B, SAAL1 | MAPK1 1900/4885AOC3 3864/4885ALDH1A1 2072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.